Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Icahn Turns Up The Heat On Amylin, Urges Board To Sell

This article was originally published in The Pink Sheet Daily

Executive Summary

The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.


Related Content

The Orphan Drug Bubble
Lilly Diabetes R&D Center Arms Firm For Battle In China
New Diabetes R&D Center Arms Eli Lilly For Battle In China
First Quarter Updates, In Brief
Deals Of The Week: Spectrum/Allos, Amgen/AstraZeneca, Forest/Janssen
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
With Lilly Out, Amylin’s Future Is Tied To Bydureon
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
Forest Holds Off Icahn, But Battle Likely Looms


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts